








Therapeutic antibodies against cancer: tools and models to understand and improve their efficacy Meeting automnal du GDR ACCITH



The research network on Antibodies and Therapeutic Targeting (GDR 3260 « Anticorps et ciblage thérapeutique ») is pleased to announce its 2013 Forum which will be held in Montpellier on November 27th. Devoted to **therapeutic antibodies against cancer: tools and models to understand and improve their efficacy**, the meeting will gather international experts who will exchange their point-of-view on the state-of-the-art and perspectives of this



Contact

gdraccith@dr8.cnrs.fr

Inscription gratuite mais obligatoire avant le 19 novembre 2013

Scientific program

Panorama on the therapeutic antibodies currently used in the clinic, the potentials, the challenges and the limitations

Véronique Blanc, Head of Biologics Discovery, Oncology Sanofi

Strategies for the isolation of innovative and original antibodies

James D Marks, School of Medicine, University of California, San Francisco, USA

The power of humanized mice in translational research

Anja Kathrin Wege, Dpt. of Gynecology and Obstetrics, Caritas Hospital St. Josef, University of Regensburg, Germany

Personalized medicine for the next generation therapies: Challenges and new Strategies *Fabien Gaire, Global Head Pathology and Tissue Analysis, Roche Diagnostics, Germany*

ImmunoPET using pretargeted peptide labeled with 68Ga in CEA positive tumors Caroline Rousseau, Nuclear Medicine Department, Comprehensive Cancer Center ICO Gauducheau, Saint Herblain, France

Exploiting innate immune populations to enhance the efficacy of therepeutic antibodies in cancer

Hans van der Vliet, Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

ATL101 (Lutetium-177 huJ591 anti-PSMA mAb) clinical results in M+ castrate resistant prostate cancer patients

Jean-Marc Le Doussal, Atlab Pharma, Nantes













